Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07VFD
|
|||
| Former ID |
DIB007873
|
|||
| Drug Name |
Mirogabalin
|
|||
| Synonyms |
Mirogabalin; 1138245-13-2; UNII-S7LK2KDM5U; DS-5565; S7LK2KDM5U; Bicyclo[3.2.0]hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1R,5S,6S)-; Bicyclo(3.2.0)hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1R,5S,6S)-; 2-((1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)acetic acid; ((1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo(3.2.0)hept-3-en-6-yl)acetic acid; Mirogabalin [INN]; Mirogabalin [USAN:INN]; [(1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid; DS5565; DS 5565; GTPL8303
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Peripheral neuropathy [ICD-11: 8C0Z] | Registered | [1] | |
| Cancer related pain [ICD-11: MG30; ICD-10: R52.1, R52.2] | Phase 3 | [2] | ||
| Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99] | Phase 3 | [3], [4] | ||
| Fibromyalgia [ICD-11: MG30.01; ICD-10: M79.7] | Phase 3 | [2] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H19NO2
|
|||
| Canonical SMILES |
CCC1=CC2C(C1)CC2(CC(=O)O)CN
|
|||
| InChI |
1S/C12H19NO2/c1-2-8-3-9-5-12(7-13,6-11(14)15)10(9)4-8/h4,9-10H,2-3,5-7,13H2,1H3,(H,14,15)/t9-,10-,12-/m1/s1
|
|||
| InChIKey |
FTBQORVNHOIASH-CKYFFXLPSA-N
|
|||
| CAS Number |
CAS 1138245-13-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) | Target Info | Modulator | [5], [6] |
| KEGG Pathway | MAPK signaling pathway | |||
| Cardiac muscle contraction | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Oxytocin signaling pathway | ||||
| Hypertrophic cardiomyopathy (HCM) | ||||
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | ||||
| Dilated cardiomyopathy | ||||
| Panther Pathway | Muscarinic acetylcholine receptor 2 and 4 signaling pathway | |||
| WikiPathways | Arrhythmogenic Right Ventricular Cardiomyopathy | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8303). | |||
| REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033181) | |||
| REF 5 | Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014 Dec;37(12):3253-61. | |||
| REF 6 | Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006 Aug;70(2):467-76. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.